Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanara MedTech Inc. (SMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sanara’s recent filings include multiple Form 8-K current reports that furnish press releases and investor materials related to financial results, strategic decisions and leadership changes.
Form 8-K filings referenced by the company cover several key areas. One set of 8-Ks furnishes press releases announcing quarterly financial results, including discussions of net revenue, segment performance and the classification of Tissue Health Plus (THP) as discontinued operations following a strategic realignment. Another 8-K furnishes a press release detailing the decision to discontinue THP operations and reallocate resources to the core surgical business. Additional 8-K disclosures address executive leadership changes, such as the appointment of a new President and Chief Executive Officer and the designation of a principal accounting officer, along with a summary of the CEO’s employment agreement.
Sanara has also filed an 8-K furnishing an investor presentation under Regulation FD, which it intends to use in meetings with investors and analysts. This presentation, provided as an exhibit, summarizes the company’s priorities and strategy for a future fiscal year and is meant to be considered alongside its other SEC filings and public announcements.
On Stock Titan, these filings can be viewed in sequence to understand how Sanara reports its financial condition, strategic realignments, executive transitions and investor communications. The platform surfaces real-time updates from EDGAR and pairs them with AI-powered summaries that explain the context and key points of each filing, helping readers quickly interpret Form 8-K disclosures, attached exhibits and other regulatory documents related to SMTI.
Sanara MedTech Inc. (SMTI) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The company furnished this information on a Form 8-K dated November 12, 2025, with the press release included as Exhibit 99.1.
The submission states that the press release and related information are furnished and not deemed “filed” under Section 18 of the Exchange Act, which limits associated liabilities. SMTI’s common stock trades on the Nasdaq Capital Market under the symbol SMTI.
Sanara MedTech Inc. (SMTI) disclosed a business update, announcing a strategic realignment that includes discontinuing operations of its Tissue Health Plus. The company communicated this decision via a press release issued on November 11, 2025, which is furnished as Exhibit 99.1.
The press release is provided for information purposes and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.
Sanara MedTech Inc. (SMTI) reported a grant of restricted common stock to CEO Seth D. Yon. The Form 4 shows the reporting person was granted 28,563 restricted shares on 09/15/2025 at no cash price, increasing his beneficial ownership to 89,851 shares. The restricted stock award was made under the company's 2024 Omnibus Long-Term Incentive Plan and vests in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028, contingent on continued employment through each vesting date. The filing is a routine Section 16 disclosure documenting the grant and resulting ownership position.
Sanara MedTech Inc. (SMTI) Form 3 shows Ashley M. Mackey reported beneficial ownership of 2,412 shares of the issuer's common stock. The report cites an event date of 08/29/2025 and the form is signed on 09/04/2025. The filing identifies the reporting person as a Director and indicates Controller in the relationship field. No derivative securities or additional holdings are reported.
Sanara MedTech Inc. announced a leadership transition and accounting role change. The Board appointed Seth D. Yon as President and Chief Executive Officer, and as a director, effective September 15, 2025, expanding the Board from eight to nine members. Yon, a long-time commercial leader at the company, receives a base salary of
Current CEO Ronald T. Nixon will resign from the CEO role on the effective date but will continue as Executive Chairman of the Board. His resignation is stated as not being due to any disagreement with the company, and his compensation will shift to director and Executive Chairman retainers. The Board also designated Ashley Mackey, the company’s Controller, as principal accounting officer, while Elizabeth B. Taylor remains Chief Financial Officer.
Sanara MedTech Inc. director and Chief Accounting & Chief Administrative Officer Michael D. McNeil reported a Form 4 showing an 08/19/2025 transaction in which 2,324 shares of common stock were withheld to satisfy tax withholding for the accelerated vesting of 9,543 restricted shares previously granted. The filing states no shares were issued or sold; the per-share withholding value was $30.86, reflecting the Nasdaq market price on the vesting date. After the withholding, Mr. McNeil beneficially owns 28,587 common shares.
Sanara MedTech Inc. reported quarterly net revenue of $25.83 million and six‑month net revenue of $49.26 million, increases versus the prior year driven by higher sales of soft tissue repair and bone fusion products. Gross profit rose to $23.89 million for the quarter, reflecting strong product margins despite modest cost of goods sold.
The company recorded a net loss attributable to shareholders of $2.01 million for the quarter (net loss per share $0.23), improved from a loss of $3.50 million the prior year quarter; year‑to‑date net loss was $5.54 million (vs. $5.27 million prior year). Cash increased to $16.96 million and total assets grew to $98.77 million. Leverage rose materially: long‑term debt, net of issuance costs, was $44.22 million (up from $30.69 million) following additional borrowings under the CRG Term Loan. The company completed the CarePICS acquisition on April 1, 2025 (total purchase consideration $3.48 million) and recorded higher investments and earnout liabilities. The period shows revenue growth and improved quarterly profitability but higher interest and contingent obligations from financing and acquisitions.
Sanara MedTech Inc. announced its financial results for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The report explicitly states the press release is furnished rather than filed, and therefore the exhibit is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings unless expressly stated.
The body of the Current Report contains no financial figures or performance metrics, so readers must consult Exhibit 99.1 for the company’s detailed results and any quantitative disclosures.
Sanara MedTech (ticker SMTI) is listed on the Nasdaq Capital Market and identifies its principal executive offices in Fort Worth, Texas.